ZSP1603 / Guangdong Zhongsheng Pharma - LARVOL DELTA

Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF） (clinicaltrials.gov) - P1/2 | N=15 | Completed | Sponsor: Guangdong Raynovent Biotech Co., Ltd | Recruiting ➔ Completed | N=36 ➔ 15

Enrollment change • Trial completion • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF） (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: Guangdong Raynovent Biotech Co., Ltd | Trial completion date: Oct 2022 ➔ Dec 2023 | Trial primary completion date: Oct 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Zhongsheng Pharmaceutical: The company's innovative drug research and development covers metabolic diseases, respiratory diseases, tumors and other therapeutic areas [Google translation] (Stockstar) - "ZSP1603, a class of innovative drug for the treatment of idiopathic pulmonary fibrosis (IPF) and malignant tumors, is currently developing Ib for the treatment of IPF / Phase IIa clinical study."

Trial status • Idiopathic Pulmonary Fibrosis • Interstitial Lung Disease • Oncology • Solid Tumor

Zhongsheng Pharmaceutical: The ZSP1603 project is conducting a Phase Ib/IIa clinical study for the treatment of IPF [Google Translation] (Eastmoney.com) - "Zhongsheng Pharmaceutical...said on the investor interaction platform on February 10 that the ZSP1603 project, a class of innovative drugs for the treatment of idiopathic pulmonary fibrosis (IPF) and malignant tumors, is currently in Phase Ib/IIa for the treatment of IPF In the clinical study, the first subject has been enrolled, which is an innovative drug that has not been marketed at home and abroad."

Trial status • Idiopathic Pulmonary Fibrosis • Oncology

Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF） (clinicaltrials.gov) - P1/2; N=36; Recruiting; Sponsor: Guangdong Raynovent Biotech Co., Ltd

Clinical • New P1/2 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Zhongsheng Pharmaceutical: Zhongsheng Ruichuang has completed the Phase Ia clinical study of ZSP1603 capsules in healthy adult subjects [Google translation] (Daily Economic News - NBD) - "Zhongsheng Ruichuang has completed the Phase Ia clinical study of ZSP1603 capsules in healthy adult subjects. The phase Ib/IIa clinical study of ZSP1603 capsule in patients with idiopathic pulmonary fibrosis (IPF) completed the enrollment and administration of the first subject in October."

Enrollment closed • Trial completion • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

Ten gold stocks that institutions are unanimously optimistic on Friday [Google translation] (Stockstar) - "...the company has signed a contract with the National Respiratory Disease Clinical Medicine Research Center (Academician Zhong Nanshan team) the strategic cooperation framework agreement....The two parties will also focus on the company’s two projects with independent intellectual property rights-the prevention and treatment of influenza A innovative drug ZSP1273 and the treatment of idiopathic Innovative pulmonary fibrosis drug ZSP1603, jointly developed an inhaled dosage form."

Licensing / partnership • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

Zhongsheng Pharmaceutical: Announcement on Obtaining International Patent Certificates by Holding Subsidiaries [Google translation] (Stockstar) - "Currently, ZSP1603 project has been completed as a Phase I clinical trial summary report and access to clinical trials, clinical trial work is on schedule and actively promoting. The core patent of the compound of the ZSP0678 project has been granted patents in the United States, Australia, Russia, Europe, Japan and other countries/regions. The core patent of the crystal form of the ZSP1603...has been granted a US patent."

Patent • Trial completion • Idiopathic Pulmonary Fibrosis

Zhongsheng Pharmaceutical: ZSP1603 project has completed Phase I clinical trials and obtained clinical trial summary report [Google translation] (Eastmoney.com) - "The ZSP1603 project has completed Phase I clinical trials and obtained a clinical trial summary report. The results of the Phase I clinical study reached the expected goal, and the project is in the phase II clinical preparation stage. The company will actively promote clinical research in accordance with scientific methods."

P1 data • Trial completion • Idiopathic Pulmonary Fibrosis

The antifibrotic effect and mechanism of a novel tyrosine kinase inhibitor, ZSP1603, in preclinical models of pulmonary fibrosis. (PubMed, Eur Rev Med Pharmacol Sci) - "ZSP1603 is an effective anti-fibrotic compound with clear mechanisms."

Journal • Preclinical • COL1A1 • PCR • TIMP1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.; Recruiting ➔ Completed; Trial completion date: Jun 2019 ➔ Oct 2019

Clinical • Trial completion • Trial completion date